Relationship between advanced glycoxidation end products, inflammatory markers/acute-phase reactants, and some autoantibodies in chronic hemodialysis patients
Language English Country United States Media print
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
12694311
DOI
10.1046/j.1523-1755.63.s84.19.x
PII: S0085-2538(15)49218-X
Knihovny.cz E-resources
- MeSH
- Autoantibodies immunology MeSH
- Biomarkers MeSH
- Kidney Failure, Chronic immunology metabolism therapy MeSH
- Renal Dialysis MeSH
- Humans MeSH
- Glycation End Products, Advanced immunology metabolism MeSH
- Acute-Phase Proteins immunology metabolism MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Names of Substances
- Autoantibodies MeSH
- Biomarkers MeSH
- Glycation End Products, Advanced MeSH
- Acute-Phase Proteins MeSH
Uremia and dialysis treatment are associated with uncorrected oxidative and carbonyl stress and microinflammation. Elevation of both oxidative/carbonyl stress end products (advanced oxidation protein products (AOPP), advanced glycation end products (AGEs), and advanced lipoperoxidation end products (ALEs), autoantibodies against modified biological structures, and acute-phase reactants (e.g., C-reactive protein [CRP], fibrinogen) seems to take part in the development of various complications, among them accelerated atherosclerosis. These pathogenic mechanisms are supposed to act synergically; nevertheless, oxidative stress shows a closer relationship to inflammation and acute-phase reaction than advanced glycation. Its end product, AOPP, could, thus, represent a biochemical marker of specific importance.
References provided by Crossref.org
